Rare complications of multikinase inhibitor treatment
ABSTRACT Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000600636&lng=en&tlng=en |
| _version_ | 1831799624816394240 |
|---|---|
| author | Fabián Pitoia Angélica Schmidt Fernanda Bueno Erika Abelleira Fernando Jerkovich |
| author_facet | Fabián Pitoia Angélica Schmidt Fernanda Bueno Erika Abelleira Fernando Jerkovich |
| author_sort | Fabián Pitoia |
| collection | DOAJ |
| description | ABSTRACT Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital. Subjects and methods: Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3.8%) received treatment with MKIs. The median age at diagnosis of these patients was 53 years (range 20-70), and 75.9% of them were women. Sorafenib was prescribed as first-line treatment to 23 patients with differentiated thyroid cancer and as second-line treatment to one patient with advanced medullary thyroid cancer (MTC). Vandetanib was indicated as first-line treatment in 6 patients with MTC and lenvatinib as second-line treatment in two patients with progressive disease under sorafenib treatment. Results: During the follow-up of treatment (mean 13.7 ± 7 months, median 12 months, range 6-32), 5/29 (17.2%) patients presented rare adverse events. These rare adverse effects were: heart failure, thrombocytopenia, and squamous cell carcinoma during sorafenib therapy and squamous cell carcinoma and oophoritis with intestinal perforation during vandetanib treatment. Conclusions: About 3 to 5 years after the approval of MKI therapy, we learned that MKIs usually lead to adverse effects in the majority of patients. Although most of them are manageable, we still need to be aware of potentially serious and rare or unreported adverse effects that can be life-threatening. |
| first_indexed | 2024-12-22T17:49:44Z |
| format | Article |
| id | doaj.art-c4d3f517f8794726b641015d9c09b5c4 |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-12-22T17:49:44Z |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-c4d3f517f8794726b641015d9c09b5c42022-12-21T18:18:13ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-429262663664010.20945/2359-3997000000090S2359-39972018000600636Rare complications of multikinase inhibitor treatmentFabián PitoiaAngélica SchmidtFernanda BuenoErika AbelleiraFernando JerkovichABSTRACT Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital. Subjects and methods: Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3.8%) received treatment with MKIs. The median age at diagnosis of these patients was 53 years (range 20-70), and 75.9% of them were women. Sorafenib was prescribed as first-line treatment to 23 patients with differentiated thyroid cancer and as second-line treatment to one patient with advanced medullary thyroid cancer (MTC). Vandetanib was indicated as first-line treatment in 6 patients with MTC and lenvatinib as second-line treatment in two patients with progressive disease under sorafenib treatment. Results: During the follow-up of treatment (mean 13.7 ± 7 months, median 12 months, range 6-32), 5/29 (17.2%) patients presented rare adverse events. These rare adverse effects were: heart failure, thrombocytopenia, and squamous cell carcinoma during sorafenib therapy and squamous cell carcinoma and oophoritis with intestinal perforation during vandetanib treatment. Conclusions: About 3 to 5 years after the approval of MKI therapy, we learned that MKIs usually lead to adverse effects in the majority of patients. Although most of them are manageable, we still need to be aware of potentially serious and rare or unreported adverse effects that can be life-threatening.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000600636&lng=en&tlng=enMultikinase inhibitorsrare adverse eventssorafenibvandetanibthyroid carcinoma |
| spellingShingle | Fabián Pitoia Angélica Schmidt Fernanda Bueno Erika Abelleira Fernando Jerkovich Rare complications of multikinase inhibitor treatment Archives of Endocrinology and Metabolism Multikinase inhibitors rare adverse events sorafenib vandetanib thyroid carcinoma |
| title | Rare complications of multikinase inhibitor treatment |
| title_full | Rare complications of multikinase inhibitor treatment |
| title_fullStr | Rare complications of multikinase inhibitor treatment |
| title_full_unstemmed | Rare complications of multikinase inhibitor treatment |
| title_short | Rare complications of multikinase inhibitor treatment |
| title_sort | rare complications of multikinase inhibitor treatment |
| topic | Multikinase inhibitors rare adverse events sorafenib vandetanib thyroid carcinoma |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000600636&lng=en&tlng=en |
| work_keys_str_mv | AT fabianpitoia rarecomplicationsofmultikinaseinhibitortreatment AT angelicaschmidt rarecomplicationsofmultikinaseinhibitortreatment AT fernandabueno rarecomplicationsofmultikinaseinhibitortreatment AT erikaabelleira rarecomplicationsofmultikinaseinhibitortreatment AT fernandojerkovich rarecomplicationsofmultikinaseinhibitortreatment |